Arrowhead Historical Balance Sheet

ARWR Stock

USD 20.23 0.28 1.40%

Trend analysis of Arrowhead Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 616.5 M, Other Current Liabilities of 103.2 M or Total Current Liabilities of 124.6 M provides information on Arrowhead Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Arrowhead Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Arrowhead Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Arrowhead Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arrowhead Pharmaceuticals is a good buy for the upcoming year.

Arrowhead Pharmaceuticals Inventory

(18.48 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

About Arrowhead Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Arrowhead Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Arrowhead Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Arrowhead Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Arrowhead currently owns. An asset can also be divided into two categories, current and non-current.

Arrowhead Pharmaceuticals Balance Sheet Chart

At this time, Arrowhead Pharmaceuticals' Accounts Payable is relatively stable compared to the past year. As of 01/31/2025, Cash is likely to grow to about 124 M, though Inventory is likely to grow to (18.5 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Arrowhead Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Arrowhead Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Arrowhead Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arrowhead Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Arrowhead Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Accounts Payable is relatively stable compared to the past year. As of 01/31/2025, Cash is likely to grow to about 124 M, though Inventory is likely to grow to (18.5 M).

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	115.2M	510.6M	587.1M	616.5M
Total Assets	765.6M	1.1B	1.3B	1.4B

Short Long Term Debt Total Total Assets

Arrowhead Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		0.9	0.92	0.87	0.52	0.94	0.74	-0.95	0.54	0.51	0.99	0.34	1.0	0.07	0.73	0.87	-0.78	0.81	0.99	0.96	0.93	1.0	0.7	0.12	0.13	0.94
Short Long Term Debt Total	0.9		0.83	0.64	0.2	0.95	0.94	-0.9	0.37	0.22	0.86	0.21	0.92	-0.19	0.54	0.69	-0.75	0.63	0.9	0.95	0.95	0.92	0.53	-0.05	-0.2	0.96
Other Current Liab	0.92	0.83		0.71	0.31	0.9	0.74	-0.9	0.43	0.31	0.94	0.63	0.9	-0.04	0.65	0.78	-0.9	0.95	0.93	0.94	0.86	0.9	0.57	0.44	0.08	0.94
Total Current Liabilities	0.87	0.64	0.71		0.65	0.73	0.41	-0.78	0.59	0.72	0.88	0.24	0.85	0.41	0.7	0.84	-0.56	0.68	0.83	0.77	0.73	0.85	0.83	0.09	0.51	0.71
Total Stockholder Equity	0.52	0.2	0.31	0.65		0.28	-0.07	-0.39	0.44	0.8	0.52	-0.1	0.51	0.44	0.62	0.66	-0.04	0.28	0.5	0.27	0.3	0.52	0.43	-0.12	0.47	0.21
Property Plant And Equipment Net	0.94	0.95	0.9	0.73	0.28		0.88	-0.95	0.6	0.27	0.93	0.28	0.94	-0.16	0.6	0.76	-0.88	0.77	0.94	0.97	1.0	0.94	0.65	0.05	-0.15	0.97
Net Debt	0.74	0.94	0.74	0.41	-0.07	0.88		-0.81	0.26	-0.13	0.72	0.19	0.75	-0.3	0.33	0.48	-0.75	0.54	0.75	0.86	0.88	0.75	0.31	-0.06	-0.42	0.89
Retained Earnings	-0.95	-0.9	-0.9	-0.78	-0.39	-0.95	-0.81		-0.57	-0.37	-0.94	-0.32	-0.95	0.06	-0.74	-0.87	0.83	-0.79	-0.97	-0.95	-0.94	-0.95	-0.65	-0.1	0.01	-0.94
Accounts Payable	0.54	0.37	0.43	0.59	0.44	0.6	0.26	-0.57		0.35	0.56	-0.1	0.5	-0.05	0.47	0.53	-0.55	0.47	0.54	0.46	0.61	0.51	0.62	-0.16	-0.07	0.42
Cash	0.51	0.22	0.31	0.72	0.8	0.27	-0.13	-0.37	0.35		0.47	0.09	0.53	0.34	0.63	0.65	-0.11	0.34	0.48	0.32	0.26	0.53	0.65	0.06	0.64	0.25
Non Current Assets Total	0.99	0.86	0.94	0.88	0.52	0.93	0.72	-0.94	0.56	0.47		0.38	0.97	0.14	0.71	0.86	-0.8	0.84	0.98	0.95	0.92	0.97	0.68	0.18	0.17	0.93
Non Currrent Assets Other	0.34	0.21	0.63	0.24	-0.1	0.28	0.19	-0.32	-0.1	0.09	0.38		0.32	-0.01	0.27	0.31	-0.58	0.77	0.35	0.42	0.19	0.31	0.25	0.96	0.35	0.43
Cash And Short Term Investments	1.0	0.92	0.9	0.85	0.51	0.94	0.75	-0.95	0.5	0.53	0.97	0.32		0.02	0.73	0.88	-0.76	0.78	0.99	0.96	0.93	1.0	0.7	0.09	0.1	0.94
Net Receivables	0.07	-0.19	-0.04	0.41	0.44	-0.16	-0.3	0.06	-0.05	0.34	0.14	-0.01	0.02		0.11	0.08	0.27	-0.01	0.01	-0.06	-0.15	0.02	0.03	0.04	0.74	-0.12
Common Stock Total Equity	0.73	0.54	0.65	0.7	0.62	0.6	0.33	-0.74	0.47	0.63	0.71	0.27	0.73	0.11		0.92	-0.46	0.61	0.79	0.62	0.59	0.73	0.54	0.15	0.26	0.59
Common Stock Shares Outstanding	0.87	0.69	0.78	0.84	0.66	0.76	0.48	-0.87	0.53	0.65	0.86	0.31	0.88	0.08	0.92		-0.59	0.72	0.92	0.78	0.74	0.88	0.69	0.16	0.28	0.74
Inventory	-0.78	-0.75	-0.9	-0.56	-0.04	-0.88	-0.75	0.83	-0.55	-0.11	-0.8	-0.58	-0.76	0.27	-0.46	-0.59		-0.89	-0.78	-0.86	-0.84	-0.76	-0.6	-0.41	0.14	-0.87
Other Current Assets	0.81	0.63	0.95	0.68	0.28	0.77	0.54	-0.79	0.47	0.34	0.84	0.77	0.78	-0.01	0.61	0.72	-0.89		0.81	0.82	0.71	0.77	0.62	0.64	0.23	0.81
Other Stockholder Equity	0.99	0.9	0.93	0.83	0.5	0.94	0.75	-0.97	0.54	0.48	0.98	0.35	0.99	0.01	0.79	0.92	-0.78	0.81		0.95	0.93	0.99	0.67	0.14	0.08	0.94
Total Liab	0.96	0.95	0.94	0.77	0.27	0.97	0.86	-0.95	0.46	0.32	0.95	0.42	0.96	-0.06	0.62	0.78	-0.86	0.82	0.95		0.96	0.96	0.65	0.18	0.0	1.0
Property Plant And Equipment Gross	0.93	0.95	0.86	0.73	0.3	1.0	0.88	-0.94	0.61	0.26	0.92	0.19	0.93	-0.15	0.59	0.74	-0.84	0.71	0.93	0.96		0.94	0.64	-0.04	-0.18	0.96
Total Current Assets	1.0	0.92	0.9	0.85	0.52	0.94	0.75	-0.95	0.51	0.53	0.97	0.31	1.0	0.02	0.73	0.88	-0.76	0.77	0.99	0.96	0.94		0.7	0.08	0.1	0.94
Short Term Debt	0.7	0.53	0.57	0.83	0.43	0.65	0.31	-0.65	0.62	0.65	0.68	0.25	0.7	0.03	0.54	0.69	-0.6	0.62	0.67	0.65	0.64	0.7		0.14	0.39	0.6
Common Stock	0.12	-0.05	0.44	0.09	-0.12	0.05	-0.06	-0.1	-0.16	0.06	0.18	0.96	0.09	0.04	0.15	0.16	-0.41	0.64	0.14	0.18	-0.04	0.08	0.14		0.42	0.19
Current Deferred Revenue	0.13	-0.2	0.08	0.51	0.47	-0.15	-0.42	0.01	-0.07	0.64	0.17	0.35	0.1	0.74	0.26	0.28	0.14	0.23	0.08	0.0	-0.18	0.1	0.39	0.42		-0.07
Non Current Liabilities Total	0.94	0.96	0.94	0.71	0.21	0.97	0.89	-0.94	0.42	0.25	0.93	0.43	0.94	-0.12	0.59	0.74	-0.87	0.81	0.94	1.0	0.96	0.94	0.6	0.19	-0.07

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	710.1M	691.9M	765.6M	1.1B	1.3B	1.4B
Short Long Term Debt Total	25.5M	81.6M	115.2M	510.6M	587.1M	616.5M
Other Current Liab	33.3M	100.4M	58.2M	85.4M	98.3M	103.2M
Total Current Liabilities	146.5M	74.1M	105.5M	103.2M	118.6M	124.6M
Total Stockholder Equity	408.8M	106.0M	271.3M	185.4M	213.3M	223.9M
Property Plant And Equipment Net	66.0M	168.6M	335.6M	431.3M	496.0M	520.8M
Net Debt	(158.9M)	(26.4M)	4.3M	407.9M	367.1M	385.4M
Retained Earnings	(644.7M)	(820.8M)	(1.0B)	(1.6B)	(1.5B)	(1.4B)
Accounts Payable	9.5M	2.9M	35.9M	11.4M	13.1M	13.8M
Cash	184.4M	108.0M	110.9M	102.7M	118.1M	124.0M
Non Current Assets Total	325.6M	315.5M	346.0M	444.3M	511.0M	536.5M
Non Currrent Assets Other	272K	29.1M	210K	4.5M	5.2M	5.4M
Cash And Short Term Investments	367.8M	376.4M	403.6M	681.0M	783.1M	822.3M
Common Stock Total Equity	187.9K	194.7K	197K	198K	227.7K	239.1K
Common Stock Shares Outstanding	103.7M	105.4M	106.8M	119.8M	137.8M	144.6M
Liabilities And Stockholders Equity	710.1M	691.9M	765.6M	1.1B	1.3B	1.4B
Inventory	3.3M	4.3M	4.4M	(21.6M)	(19.5M)	(18.5M)
Other Current Assets	6.6M	27.5M	15.9M	14.5M	16.7M	17.5M
Other Stockholder Equity	1.1B	1.2B	1.3B	1.8B	2.1B	2.2B
Total Liab	301.3M	586.0M	478.4M	948.7M	1.1B	1.1B
Property Plant And Equipment Gross	88.9M	110.3M	377.5M	489.3M	562.7M	590.8M
Total Current Assets	384.6M	376.4M	419.5M	695.5M	799.8M	839.8M
Accumulated Other Comprehensive Income	(69K)	(136K)	(3.2M)	4.8M	5.5M	5.7M
Short Term Debt	4.5M	5.6M	9.7M	6.3M	7.3M	7.7M
Common Stock	197K	106.0M	200K	217K	249.6K	237.1K
Current Deferred Revenue	19.3M	111.1M	74.1M	866K	995.9K	946.1K
Non Current Liabilities Total	154.8M	511.9M	372.9M	845.6M	972.4M	1.0B
Property Plant Equipment	30.9M	48.7M	110.3M	335.6M	385.9M	405.2M
Other Assets	68.9M	96.8M	218K	210K	241.5K	229.4K
Short Term Investments	183.4M	268.4M	292.7M	578.3M	665.0M	698.3M
Intangible Assets	13.7M	12.0M	10.3M	8.6M	9.8M	10.2M
Other Liab	8.7M	41.4M	190.3M	56.0M	64.3M	67.6M
Net Tangible Assets	446.4M	395.2M	398.5M	261.1M	300.2M	202.9M

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.

The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arrowhead Historical Balance Sheet

Arrowhead Pharmaceuticals Inventory

(18.48 Million)

About Arrowhead Balance Sheet Analysis

Arrowhead Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Arrowhead Pharmaceuticals balance sheet Correlations

Arrowhead Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arrowhead Pharmaceuticals balance sheet Accounts

Pair Trading with Arrowhead Pharmaceuticals

Additional Tools for Arrowhead Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Liabilities Total	+ 1.0	Total Liab
Non Current Assets Total	+ 0.99	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Total Current Assets	- 0.95	Retained Earnings
Total Liab	- 0.95	Retained Earnings
Cash And Short Term Investments	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Property Plant And Equipment Net
Retained Earnings	- 0.95	Total Assets